Loading
Alemtuzumab (Campath) is an antibody that wipes out lymphocytes carrying the CD52 marker. It is approved for chronic lymphocytic leukaemia and is supplied in the US through a restricted distribution programme.
Alemtuzumab is a CD52-directed cytolytic antibody approved by the FDA in 2001 (accelerated) for fludarabine-refractory B-cell CLL, with full approval as a single agent for B-CLL after the CAM307 randomised trial against chlorambucil in previously untreated patients (297 randomised; longer progression-free survival on alemtuzumab). Profound lymphopenia brings cytomegalovirus reactivation and opportunistic infection, so prophylaxis and monitoring are mandatory. In the EU, MabCampath was authorised in 2001 and withdrawn in 2012 when the sponsor repositioned the molecule as Lemtrada for multiple sclerosis; Campath remains available for CLL through the US Campath Distribution Program. It is also used off label as lymphodepleting conditioning in stem cell transplantation.
Backbone ribbon from PDB 1CE1. RCSB PDB 1CE1. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Humanised IgG1 that binds CD52 on B and T lymphocytes, monocytes and NK cells; kills by antibody-dependent cellular cytotoxicity and complement-dependent lysis. Connects to CD52.
1.Alemtuzumab binds CD52.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
B-cell CLL treated with alkylating agents and failed fludarabine therapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
B-cell CLL treated with alkylating agents and failed fludarabine therapy
Confirmed: the accelerated approval of 2001 converted to traditional approval 6.4 years after it was granted.
| Region | Year | Indication |
|---|---|---|
| US | 2001 | B-cell chronic lymphocytic leukaemia (single agent) |
| EU | 2001 | B-CLL after fludarabine (MabCampath; authorisation withdrawn 2012) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Alemtuzumab" OR ABSTRACT:"Alemtuzumab" OR TITLE:"Campath" OR ABSTRACT:"Campath" OR TITLE:"MabCampath" OR ABSTRACT:"MabCampath" OR TITLE:"Lemtrada multiple sclerosis formulation" OR ABSTRACT:"Lemtrada multiple sclerosis formulation") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Alemtuzumab, not a curated reading list.
Shares Sezary syndrome, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types).
Shares T-cell large granular lymphocytic leukaemia, Sezary syndrome, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types).
Shares Sezary syndrome, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Monoclonal antibodies, Non-Hodgkin lymphoma (all types).
Shares T-cell large granular lymphocytic leukaemia, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Infection prophylaxis in lymphoma: PJP, herpes, fungal risk and vaccination, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types).
Shares T-cell prolymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares CD52, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types).
Shares CD52, Sezary syndrome, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Monoclonal antibodies.